Promote Your Research… Share it Worldwide
Have a story or a research paper to share? Become a contributor and publish your work on AcademicJobs.com.
Submit your Research - Make it Global NewsSingapore's Bold Step in Lung Cancer Research: The CLARION Programme
Singapore's research ecosystem has received a major boost with a S$25 million grant awarded to the Conquering Lung Cancer Across All Stages with Research and InnovatiON (CLARION) programme. Led by Professor Daniel Tan from the National Cancer Centre Singapore (NCCS), this initiative brings together experts from leading universities and research institutes to address lung cancer in Asian patients. Lung cancer remains Singapore's deadliest cancer, claiming three lives daily, with nearly half of cases occurring in never-smokers—a stark contrast to Western patterns where smoking dominates.
The programme, funded by the National Medical Research Council (NMRC) under its Open Fund-Large Collaborative Grant, aims to revolutionize care from risk prediction to advanced therapies. Universities like the National University of Singapore (NUS) through its National University Cancer Institute (NCIS) and Duke-NUS Medical School play pivotal roles, highlighting Singapore's higher education institutions as hubs for precision medicine innovation.
The Unique Challenge of Lung Cancer in Asian Populations
In Asia, lung cancer strikes differently. While globally it's tied to tobacco use, up to 50 percent of Singapore patients have never smoked, often developing non-small cell lung cancer (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations. These genetic alterations occur in 40 to 60 percent of Asian cases, compared to 10 to 15 percent in Western populations, making targeted therapies like osimertinib standard but prone to resistance within 9 to 15 months.
Never-smokers, particularly homemakers exposed to secondhand smoke or pollution, face heightened risks. Family history elevates odds significantly, as shown in Taiwan's screening where 2 percent of 12,000 high-risk non-smokers had undetected cancer. In Singapore, 60 percent of diagnoses happen at late stages, underscoring the need for better early detection tools tailored to Asian biology.
University Powerhouses Driving CLARION
Singapore's universities are at the heart of CLARION. NUS's NCIS, part of the National University Health System (NUHS), contributes through Dr. Huang Yiqing, co-lead on screening efforts. Duke-NUS Medical School, affiliated with SingHealth, provides expertise in translational research, building on prior NMRC grants totaling S$20 million since 2013.
A*STAR's Genome Institute of Singapore (GIS), collaborating closely with university teams, leads genomics. Associate Professor Tam Wai Leong from GIS and Dr. Tee Wee Wei from A*STAR's Institute of Molecular and Cell Biology (IMCB) spearhead multi-omics analysis on patient cohorts. This academic-industry synergy positions Singapore universities as global leaders in Asian-centric oncology.
Revolutionizing Screening: SOLSTICE and POPULUS Initiatives
Early detection is CLARION's cornerstone. The SOLSTICE study, launched two years ago, uses low-dose computed tomography (LDCT) scans on family members of lung cancer patients, identifying cases in high-risk never-smokers. POPULUS expands this population-wide, identifying at-risk groups beyond family history, such as those exposed to urban pollution.
University researchers at NCIS are refining risk models to avoid over-screening while catching 60 percent late-stage misses. This could mirror Taiwan's success, where LDCT reduced mortality by 20 percent in high-risk groups. For Singapore students in medicine and public health at NUS, these projects offer hands-on training in epidemiology and imaging AI.
Photo by CFPhotosin Photography on Unsplash
Overcoming Drug Resistance: Genomics and Biomarker Breakthroughs
EGFR-targeted drugs fail due to resistance, a focus for GIS and IMCB. Using multi-omics—genomics, transcriptomics, proteomics—teams map resistance mechanisms in Asian tumors. Predictive models will guide therapies, potentially extending remission.
NUS and Duke-NUS labs integrate AI for biomarker discovery, analyzing thousands of samples. This work not only advances treatments but trains PhD students in bioinformatics, a booming field. For details on the genomics approach, see the A*STAR GIS announcement.
Personalized Therapies and Immunotherapy for Never-Smokers
CLARION's Theme 2 enhances immunogenicity in lung cancer in never-smokers (LCINS), identifying druggable targets. Theme 3 targets cellular plasticity causing resistance. University-led trials like Alkove-1 test novel drugs like NVL-655.
Multidisciplinary clinics at NCCS and NCIS will deliver tailored plans. Duke-NUS's immunology experts explore why Asian tumors evade immune attacks, paving for CAR-T or checkpoint inhibitors suited to local genetics.
Collaborative Ecosystem: From Labs to Clinics
Partners span NCCS, NCIS, GIS, IMCB, IHPC, SGH, TTSH. This network fosters student exchanges, joint PhDs, and postdocs. NUS Medicine students rotate in CLARION labs, gaining real-world data science and oncology skills.
The grant builds on S$10 million prior funding, solidifying Singapore's role in Asia-Pacific research. Prof. Tan notes: "We aim to understand why lung cancer behaves differently in Asians."
Boosting Higher Education and Research Careers
CLARION elevates Singapore universities. NUS and Duke-NUS attract top talent, offering funded PhDs in precision oncology. Postdoc positions in biomarkers and AI screening proliferate, with salaries competitive at S$60,000-S$100,000 annually.
For aspiring researchers, programmes like this provide mentorship from PIs like Prof. Tan and A/Prof. Tam. Check NCCS updates for opportunities.
Photo by Timothy Chambers on Unsplash
Challenges Ahead and Global Implications
Challenges include ethical screening, data privacy in multi-omics, and scaling POPULUS. Pollution's role needs clarification. Yet, success could cut mortality 20-30 percent via early detection.
For Asia's 1 billion never-smokers, CLARION sets precedents. Singapore universities lead, exporting models to high-burden nations.
Future Outlook: A New Era for Asian Oncology
By 2030, CLARION envisions routine LDCT for high-risk Asians, resistance-proof therapies, and survival doubling. Universities will spawn spin-offs, boosting biotech jobs. Students today shape tomorrow's cures, making Singapore a oncology powerhouse.
This grant underscores higher education's role in national health, inspiring interdisciplinary careers.
Be the first to comment on this article!
Please keep comments respectful and on-topic.